Navigation Links
El Camino Hospital Announces First Implant in Clinical Trial to Evaluate Revolutionary Heart Valve Procedure
Date:12/21/2010

MOUNTAIN VIEW, Calif., Dec. 21 2010 /PRNewswire/ -- El Camino Hospital today announced its first patient implant in the Medtronic CoreValve® U.S. Clinical Trial. El Camino Hospital is one of the first of 40 hospitals across the U.S. to participate in the trial, which is evaluating a revolutionary non-surgical, less-invasive procedure as a treatment alternative to open-heart surgery for patients with severe aortic stenosis.

"The Heart and Vascular Institute at El Camino Hospital is proud to have been chosen among a very select group of leading hospitals across the nation to participate in the CoreValve Trial," said Dr. James Joye, Co-primary investigator (PI) of the CoreValve study and Director of Research and Education for the Heart & Vascular Institute at El Camino Hospital. "The CoreValve technology and the ability to perform aortic valve replacement without open heart surgery represent the most significant advance in valvular heart disease in decades. Combined with our involvement with the clinical evaluation of the percutaneous mitral valve repair, the addition of CoreValve uniquely distinguishes The Heart and Vascular Institute as an epicenter for minimally invasive heart valve intervention."

Aortic stenosis prevents the heart's aortic valve from opening completely, thereby preventing healthy blood flow from the aorta to the rest of the body. Untreated, aortic valve stenosis leads to serious heart problems. Worldwide, approximately 300,000 people have been diagnosed with aortic stenosis (100,000 in the U.S.), and approximately one-third of these patients are deemed at too high a risk for open-heart surgery(i), the only therapy with significant clinical effect that is currently available in the United States.

In the clinical trial, physicians channel a catheter (thin tube) with a porcine, prosthetic valve through a small opening in the patient's femoral artery to reach the heart. The physician guides the CoreValve System to the aortic valve, where it self-expands to replace the diseased aortic valve; the procedure is completed without open-heart surgery or surgical removal of the native valve.

"A potentially new era in the treatment of severe aortic stenosis is on the horizon," said Dr. Vincent Gaudiani, Co-PI of the CoreValve study and cardiovascular surgeon at El Camino Hospital. "We are excited to participate in the early clinical evaluation of the CoreValve technology and are hopeful this will become a new treatment option for patients suffering from aortic stenosis. Ultimately the goal is to improve survival rates for these very sick patients, for whom limited therapies are available today."

In the U.S., the CoreValve System will not be commercially available until the successful completion of this clinical trial and approval by the U.S. Food and Drug Administration (FDA). The CoreValve System received CE (Conformite Europeenne) Mark in Europe in 2007.

About Aortic Stenosis

Aortic stenosis, which is most prevalent in the elderly population, inhibits blood flow between the heart and the body and causes symptoms such as shortness of breath, chest pain, fatigue, and heart palpitations. While the heart initially compensates for stenosis by thickening its walls to help push blood through the valve, eventually this extra work weakens the heart and leads to an insufficient supply of oxygen-rich blood and sometimes causes a back-up of blood into the lungs. Untreated, aortic valve stenosis can lead to serious heart problems including heart failure and even death. Other than surgery, patients with this condition have had few, if any, successful treatment options.

About El Camino Hospital

El Camino Hospital, ranked among the top five percent of hospitals nationwide for clinical excellence by HealthGrades for five consecutive years, is an acute care, 542-bed, not-for-profit and locally-governed organization with campuses in Mountain View and Los Gatos, Calif. In addition to a state-of-the-art emergency department, key medical specialty focuses include cancer care, heart and vascular, neuroscience, genomic medicine, orthopedic and spine and women's health. El Camino Hospital has delivered the highest level of medical services to the communities of Silicon Valley for more than four decades. The hospital is also recognized as a national leader in the use of health information technology to promote patient safety, including computerized order entry, electronic medical records and wireless communications. El Camino Hospital was the pioneer hospital for computerized physician order entry (CPOE), having started its program in 1971.  Additionally El Camino Hospital is an accredited Mega Heart and Certified Chest Pain Center and a Santa Clara County Certified STEMI Receiving Center, and a Joint Commission certified stroke center.  To learn more about El Camino Hospital, the services it provides in Mountain View and Los Gatos, and its commitment to doing "Whatever it Takes" to provide the best and safest patient care, visit www.elcaminohospital.org.

Information about the clinical trial is available at www.clinicaltrials.gov.

(i) Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: Why are so many denied surgery? Eur Heart J. 2003;26:2714-2720.


'/>"/>
SOURCE El Camino Hospital
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System
2. Hospital Marketplace E-Course Suite Adds Insight on Quality and Information Systems
3. Terso Solutions RFID Jump Start Takes the Risk Out of Implementing RFID for Hospitals and Research Laboratories Looking to Streamline Operations and Improve Regulatory Compliance
4. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
5. Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use
8. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
9. Vanderbilt University Hospital Selects Allscripts Care Management
10. Health Robotics to Showcase CytoCare at ISOPP (May 2010) and Charles University General Faculty Hospital of Prague
11. MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):